Status:
COMPLETED
Safety and Effectiveness of Omega 3-Fatty Acids, EPA Versus DHA, for the Treatment of Major Depression
Lead Sponsor:
Massachusetts General Hospital
Collaborating Sponsors:
Cedars-Sinai Medical Center
National Institute of Mental Health (NIMH)
Conditions:
Major Depressive Disorder
Eligibility:
All Genders
18-80 years
Phase:
PHASE3
Brief Summary
This study examines the difference in the effectiveness of two natural compounds, eicosapentanoic (EPA) and docosahexanoic (DHA)omega-3 fatty acids, in treating major depressive disorder. Both types o...
Detailed Description
The study lasts for eight weeks and involves four visits after the screen and baseline visits (biweekly). Participants will be randomized, or chosen by chance, to enter into one of three groups. Peopl...
Eligibility Criteria
Inclusion
- Men or women aged 18-80 years old.
- Must meet criteria for current Major Depressive Disorder.
Exclusion
- Serious or unstable medical illness including cardiovascular, hepatic, renal, respiratory, endocrine, neurologic, or hematologic disease
- History of seizure disorder.
- Substance use disorders, including alcohol, active within the last six months (past history is OK).
- History of multiple adverse drug reactions or allergy to the study drugs.
Key Trial Info
Start Date :
July 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 1 2013
Estimated Enrollment :
196 Patients enrolled
Trial Details
Trial ID
NCT00361374
Start Date
July 1 2006
End Date
March 1 2013
Last Update
July 18 2014
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Depression Clinical Research Program, Massachusetts General Hospital
Boston, Massachusetts, United States, 02114